Your browser doesn't support javascript.
loading
Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy.
Ciric, Milica Zrnic; Ostojic, Miodrag; Baralic, Ivana; Kotur-Stevuljevic, Jelena; Djordjevic, Brizita I; Markovic, Stana; Zivkovic, Stefan; Stankovic, Ivan.
Affiliation
  • Ciric MZ; Department of Bromatology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
  • Ostojic M; Faculty of Medicine, University of Belgrade, 6 Dr Subotica Street, 11000 Belgrade, Serbia.
  • Baralic I; Institute for Cardiovascular Diseases "Dedinje", Milana Tepica 1, 11000 Belgrade, Serbia.
  • Kotur-Stevuljevic J; Department of Cardiology, University Clinical Centre of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina.
  • Djordjevic BI; Medical Faculty, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina.
  • Markovic S; Department of Pharmacy, Zvezdara University Medical Center, Dimitrija Tucovica 161, 11000 Belgrade, Serbia.
  • Zivkovic S; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
  • Stankovic I; Department of Bromatology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
Nutrients ; 13(3)2021 Mar 10.
Article in En | MEDLINE | ID: mdl-33802219
ABSTRACT
Dietary supplementation with sugar cane derivates may modulate low-density lipoprotein cholesterol (LDL-C) and proprotein convertase subtilisin/kexin type 9 (PCSK9) levels. The purpose of this study was to determine if dietary supplement (DS), containing Octacosanol (20 mg) and vitamin K2 (45 µg), could restore the disrupted physiologic relation between LDL-C and serum PCSK9. Double-blind, randomized, placebo-controlled, single-center study including 87 patients on chronic atorvastatin therapy was conducted. Eighty-seven patients were randomized to receive DS (n = 42) or placebo (n = 45), and followed for 13 weeks. Serum PCSK9 levels, lipid parameters and their relationship were the main efficacy endpoints. The absolute levels of PCSK9 and LDL-C were not significantly different from baseline to 13 weeks. However, physiologic correlation between % change of PCSK9 and % change of LDL-C levels was normalized only in the group of patients treated with DS (r = 0.409, p = 0.012). This study shows that DS can restore statin disrupted physiologic positive correlation between PCSK9 and LDL-C. Elevated PCSK9 level is an independent risk factor so controlling its rise by statins may be important in prevention of cardiovascular events.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dietary Supplements / Fatty Alcohols / Proprotein Convertase 9 / Cholesterol, LDL Type of study: Clinical_trials / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Nutrients Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dietary Supplements / Fatty Alcohols / Proprotein Convertase 9 / Cholesterol, LDL Type of study: Clinical_trials / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Nutrients Year: 2021 Document type: Article